Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

 
• By Alaric DeArment
lung illustration
Merck announced Phase III interim data for Keytruda in adjuvant NSCLC • Source: Shutterstock

More from Anticancer

More from Therapy Areas